Sonali Bloom.
BOSTON—20/20 Onsite, a mobile optometry and life sciences company, announced the appointment of Sonali Bloom as its new chief executive officer. Bloom moved up from the role of vice president of product and experience earlier this spring, with four-year tenure at the company. She is honored to lead and guide the team in its mission to make high-quality vision care more widely accessible, according to an announcement from 20/20 Onsite. Bloom first joined 20/20 Onsite in 2017 as a post-MBA intern. 

Since joining full time in 2018, Bloom has held various leadership roles across client success, marketing, sales, technology, product development and operations. Most recently, she led the Life Sciences business unit, which is focused on serving biopharma sponsors and CROs conducting clinical research, becoming intimately familiar with the company’s work in clinical research and its growth potential. Launched in the summer of 2020, the company’s Life Sciences practice conducts pre-screening for patients who may be eligible for clinical research, eye health assessments for clinical trial participants, and post-marketing safety surveillance programs.

“20/20 Onsite is exceedingly fortunate to have someone with Sonali Bloom’s experience, skills, education, and motivation taking on the CEO role at this exciting inflection point in the company’s growth,” said Tony Morris, board chair of 20/20 Onsite. “Sonali has demonstrated both insightful understanding of the opportunities we are addressing as well as leadership, agility, and operational effectiveness in advancing our mobile care delivery model in two very large and complementary markets.”

Bloom holds a BS in Physics from Yale University and an MBA with Distinction from Harvard Business School.

As someone who can barely see without glasses, Bloom feels very connected to 20/20 Onsite’s mission to go the extra mile to make high-quality vision care more accessible, creating healthier and happier patients, families, and communities. “At 20/20 Onsite, we place our patients at the center of all we do. We take every opportunity to bring care directly to patients who wouldn’t otherwise receive care, endeavoring to eliminate every friction or inconvenience along the way,” said Bloom.

Bloom has played an integral role in 20/20 Onsite’s innovations to date, including being a driving force behind the company’s recent rebrand, the launch of three new Mobile Vision Clinics and the restart of the pro bono Boston Public Schools program in the first quarter of 2022. Before the pandemic, she led the development and growth of the routine optometry business. During the pandemic shutdown, she oversaw the reengineering of customer success processes and delivery capacity including the refinement of the integrated systems backbone that guides operations, the announcement said.

“Sonali’s perspectives, creativity, and energy have helped us grow to where we are today,” added Ivan Quiroz, vice president, clinic operations. “I’ve seen Sonali tackle challenges and adapt to circumstances that would break most leaders, and I am excited to help 20/20 Onsite accelerate its impact with Sonali in the driver’s seat.”

Former CEO Alexis McLaughlin left the company in April, and is returning to her consumer retail roots as the CEO of a startup in the veterinary care market. “We thank Alexis and wish her great success in her new venture,” said Morris. “The Board and I are greatly looking forward to Sonali’s energetic leadership as 20/20 Onsite brings a compelling solution to the patient access challenge faced throughout the health care and wellness sectors.”

20/20 Onsite is on target to nearly double its business activity this year due to the expansion of its Life Sciences practice and the growing client list in its Routine Optometry practice. The team continues to deliver new innovations in vision care and shows no signs of slowing down.

20/20 Onsite serves 400+ corporate clients, educational institutions, and other organizations with comprehensive eyecare for their employees, and their patient base of 70,000+ consistently reports NPS over 92.